220 related articles for article (PubMed ID: 12908853)
21. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
Zhang Y; Benet LZ
Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
[TBL] [Abstract][Full Text] [Related]
22. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo drug interactions involving human CYP3A.
Thummel KE; Wilkinson GR
Annu Rev Pharmacol Toxicol; 1998; 38():389-430. PubMed ID: 9597161
[TBL] [Abstract][Full Text] [Related]
24. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
25. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
[TBL] [Abstract][Full Text] [Related]
26. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
28. CYP3A in horse intestines.
Tydén E; Olsén L; Tallkvist J; Larsson P; Tjälve H
Toxicol Appl Pharmacol; 2004 Dec; 201(2):112-9. PubMed ID: 15541751
[TBL] [Abstract][Full Text] [Related]
29. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
30. Posttranscriptional elevation of cytochrome P450 3A expression.
Zangar RC; Hernandez M; Novak RF
Biochem Biophys Res Commun; 1997 Feb; 231(1):203-5. PubMed ID: 9070249
[TBL] [Abstract][Full Text] [Related]
31. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse.
Cantoni L; Rozio M; Mangolini A; Hauri L; Caccia S
Toxicol Sci; 2003 Sep; 75(1):25-30. PubMed ID: 12857935
[TBL] [Abstract][Full Text] [Related]
32. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Lu H; Waxman DJ
Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
Lee E; Shon JC; Liu KH
Biopharm Drug Dispos; 2016 Sep; 37(6):366-72. PubMed ID: 27323294
[TBL] [Abstract][Full Text] [Related]
35. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
[TBL] [Abstract][Full Text] [Related]
36. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
39. Posttranslational elevation of cytochrome P450 3A levels and activity by dimethyl sulfoxide.
Zangar RC; Novak RF
Arch Biochem Biophys; 1998 May; 353(1):1-9. PubMed ID: 9578594
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
